WATERTOWN, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands. Presentations will include information about the company’s lead drug candidate, eravacycline, as well as data from its preclinical TP-6076 program.
The details for the data presentations at ECCMID are as follows:
Eravacycline presentations:
Poster title: Eravacycline in vitro activity against clinical isolates obtained from urinary and gastro-intestinal sources, including drug-resistant phenotypes, from patients in Europe
Date and time: Saturday, April 9 from 3:30 – 4:30 p.m. CEST
Location: Poster Area
Poster number: #P0342
Session info: Susceptibility trends for old and new antibiotics; Paper poster session
Poster title: In vitro activity of eravacycline and comparators in Gram-negative organisms, including drug-resistant phenotypes, isolated from respiratory sources in Europe
Date and time: Saturday, April 9 from 3:30 – 4:30 p.m. CEST
Location: Poster Area
Poster number: #P0343
Session info: Susceptibility trends for old and new antibiotics; Paper poster session
Poster title: In vitro activity of eravacycline and comparators against Enterobacteriaceae, including subgroups of strains with resistance to carbapenems or 3rd/4th generation cephalosporins, isolated from patients in the Europe
Date and time: Saturday, April 9 from 3:30 – 4:30 p.m. CEST
Location: Poster Area
Poster number: #P0344
Session info: Susceptibility trends for old and new antibiotics; Paper poster session
Poster title: In vitro activity of eravacycline and comparators against Acinetobacter baumannii, including carbapenem-resistant strains, and Stenotrophomonas maltophilia isolated from patients in Europe
Date and time: Saturday April 9 from 3:30 – 4:30 p.m. CEST
Location: Poster Area
Poster number: #P0265
Session info: Focus Acinetobacter; Paper poster session
Poster title: TP-6076 is efficacious in a mouse pneumonia model with carbapenem-resistant Acinetobacter baumannii (CRAB) and retains potency against common tetracycline-resistance mechanisms
Date and time: Monday, April 11 from 1:30 – 2:30 p.m. CEST
Location: Poster Area
Poster number: #P1310
Session info: New Antibiotics against Gram-negative bacteria; Paper poster session
Full abstracts can be found on the ECCMID website at http://www.eccmid.org/.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes its late-stage broad-spectrum antibiotic, eravacycline, as well as two additional antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in preclinical studies and early or interim clinical trials will be indicative of results obtained in future clinical trials; whether eravacycline will advance through the clinical trial process; whether the results of the Company's development efforts will warrant regulatory submission and whether any such submissions will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; whether our cash resources will be sufficient to fund our continuing operations for the period anticipated; and other factors discussed in the "Risk Factors" section of our annual report on Form 10-K, filed with the Securities and Exchange Commission on February 25, 2016. In addition, the forward-looking statements included in this press release represent our views as of April 7, 2016. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.